Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.70 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190999 | 0.98 | KEAP1 (0.72) | KEAP1NFE2L2NPC1RAB9ACHRM3 | |
| SCHEMBL198082 | 0.84 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL29903954 | 0.84 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL1235433 | 0.84 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL198312 | 0.84 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL2764243 | 0.84 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3909615 | 0.84 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL2763493 | 0.83 | KEAP1 (0.70) | KEAP1NFE2L2RAB9ACHRM3CHRM2 | |
| SCHEMBL2763519 | 0.83 | KEAP1 (0.70) | KEAP1NFE2L2NPC1RAB9ACHRM3 | |
| Hydrochloric Acid SCHEMBL6004238 | 0.83 | KEAP1 (0.93) | KEAP1NFE2L2CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2177511-A2 | Process for preparing 3,6-disubstituted azabicyclo derivatives | Ranbaxy Laboratories Limited (IN) | 2010-04-21 | — | — | EP | disclosed |
| EP-1572648-B1 | 3,6-DISUBSTITUTED AZABICYCLO (3.1.0)-HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2008-07-09 | — | — | EP | disclosed |
| US-7232835-B2 | 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-06-19 | — | — | US | disclosed |
| US-20060217432-A1 | 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-09-28 | — | — | US | disclosed |
| EP-1572648-A1 | 3,6-DISUBSTITUTED AZABICYCLO (3.1.0)-HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052857-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217432-A1 | 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | KEAP1 1479/4885NFE2L2 3687/4885NPC1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.